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Evaluation and Treatment of Pericarditis
A Systematic Review
Massimo Imazio, MD; Fiorenzo Gaita, MD; Martin LeWinter, MD
P ericarditis is the most common form of pericardial diseaseworldwide.1-10Pericarditisusuallyaffectsyoungandmiddle-aged individuals and frequently recurs.1,2 In a prospective,
observational cohort study involving2generalhospitals froman Ital-
ian urban area of 220 000 inhabitants, an incidence of 27.7 cases
per 100 000populationperyearwas reported.3Data fromaFinnish
national registry4demonstratedastandardized incidencerateofhos-
pitalizations for acute pericarditis of 3.32 per 100 000 person-
years, with a higher proportion of men. Overall, pericarditis ac-
counts for 0.2% of all hospital cardiovascular admissions4 and is
diagnosed in approximately 5%ofpatientswithnonischemic chest
pain in emergency departments in North America and Western
Europe.5,6 In developed countries, the in-hospital mortality rate is
approximately 1.1%. Prognosis is determined in part by patient age
and etiology.4,7
Pericarditismaybe amanifestation of underlying systemic dis-
easeor aprimaryprocess unrelated to systemic disease (Box 1).8-10
Limited epidemiological data are available, and the exact incidence
is difficult to estimate becausemild casesmay resolvewithout a di-
agnosis.However, failure to recognizeandtreatpericarditismaypro-
long the disease course and increase recurrences.11,12
Evidence for pericarditis therapy has advanced in the last
10 years. The first randomized clinical trials (RCTs)1,2,13-18 and obser-
vational studies7,19 have likely contributed to improved outcomes
IMPORTANCE Pericarditis is the most common form of pericardial disease and a relatively
common cause of chest pain.
OBJECTIVE To summarize published evidence on the causes, diagnosis, therapy, prevention,
and prognosis of pericarditis.
EVIDENCE REVIEW A literature search of BioMedCentral, Google Scholar, MEDLINE, Scopus,
and the Cochrane Database of Systematic Reviews was performed for human studies without
language restriction from January 1, 1990, to August 31, 2015. After literature review and
selection of meta-analyses, randomized clinical trials, and large observational studies, 30
studies (5 meta-analyses, 10 randomized clinical trials, and 16 cohort studies) with 7569 adult
patients were selected for inclusion.
FINDINGS The etiology of pericarditis may be infectious (eg, viral and bacterial) or
noninfectious (eg, systemic inflammatory diseases, cancer, and post–cardiac injury
syndromes). Tuberculosis is a major cause of pericarditis in developing countries but accounts
for less than 5% of cases in developed countries, where idiopathic, presumed viral causes are
responsible for 80% to 90% of cases. The diagnosis is based on clinical criteria including
chest pain, a pericardial rub, electrocardiographic changes, and pericardial effusion. Certain
features at presentation (temperature >38°C [>100.4°F], subacute course, large effusion or
tamponade, and failure of nonsteroidal anti-inflammatory drug [NSAID] treatment) indicate a
poorer prognosis and identify patients requiring hospital admission. Themost common
treatment for idiopathic and viral pericarditis in North America and Europe is NSAID therapy.
Adjunctive colchicine can ameliorate the initial episode and is associated with approximately
50% lower recurrence rates. Corticosteroids are a second-line therapy for those who do not
respond, are intolerant, or have contraindications to NSAIDs and colchicine. Recurrences may
occur in 30% of patients without preventive therapy.
CONCLUSIONS AND RELEVANCE Pericarditis is themost common form of pericardial disease
worldwide andmay recur in as many as one-third of patients who present with idiopathic or
viral pericarditis. Appropriate triage and treatment with NSAIDs may reduce readmission
rates for pericarditis. Treatment with colchicine can reduce recurrence rates.
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and reduced recurrences1,2,7,13-23 Well-defined criteria for diagnosis,
integrated imaging, and diagnostic workup have been recently
proposed.20,21 This review summarizes current evidence regarding
the causes, diagnosis, therapy, prevention, and prognosis of
pericarditis.
Methods
A literature search of BioMedCentral, Google Scholar, MEDLINE,
Scopus, and theCochraneDatabaseofSystematicReviewswasper-
formed for human studies without language restriction from Janu-
ary 1, 1990, to August 31, 2015, using the search terms pericarditis,
diagnosis,drug therapy, andprognosis. Potentially relevant articles
were reviewed to exclude duplicates and to ensure they included
patients with objectively confirmed pericarditis. The review in-
cluded meta-analyses, clinical trials, and large observational stud-
ies with at least 100 patients (eFigure 1 in the Supplement). Avail-
able levels of evidence for each diagnostic and therapeutic
intervention were reviewed and classified according to American
HeartAssociation/AmericanCollegeofCardiologyguidelines (eTable
1 in the Supplement).
Data have been prioritized to emphasize the highest quality
of evidence, defined as RCTs and meta-analyses. Findings of the
present analysis were compared with current guidelines and con-
sensus statements.
Results
Thirty-one studies (5 meta-analyses, 10 RCTs, and 16 cohort stud-
ies) with 7569 adult patients were selected for inclusion (eFigure 1
in the Supplement).
Pathophysiology
The etiology of pericarditismay be categorized as infectious or non-
infectious (Table 1). The prompt recognition of a likely cause of peri-
carditis may be critical. In developing countries with a high preva-
lence of tuberculosis, tuberculosis accounts for about 70% of
pericarditisdiagnosesandhasahighmortality:about25%at6months
in theabsenceofhuman immunodeficiencyvirus (HIV) infectionand
approximately 40% in thosewith associatedHIV infection.8,9
Tuberculous pericarditis is much less common in developed
countries, accounting for less than 5%of all cases.19,23-26 Immigra-
tionmay increase these cases in developed countries.9
InWestern Europe and North America, about 80% to 90% of
cases are labeled “idiopathic” after a diagnostic workup, and most
are presumed to be viral.5,6 The remaining cases with an identified
etiology include, in unselected populations, neoplastic pericardial
disease (5%-10%), systemic inflammatory diseases and pericardial
injurysyndromes (2%-7%), tuberculouspericarditis (about4%),and
purulent pericarditis (<1%) (Table 1).19,24,25 In a recent French study
consisting of patients hospitalizedwith acute pericarditis admitted
fromtheemergencydepartmentor fromcardiologyandcardiac sur-
gery departments, the etiologies of acute pericarditis were idio-
pathic in 516 of 933 (55%), autoimmuneor post–cardiac injury syn-
dromes in 222of933 (24%), neoplastic in83of933 (9%), bacterial
in29of933(3.1%),andtuberculosis inonly5cases (0.5%).Thisstudy
suggests that hospitalized patients are usually more complicated
cases with a higher risk of a nonidiopathic etiology.26 Moreover, in
developedcountries, theagingof thepopulation,with increaseduse
of cardiovascular interventions (eg, percutaneous coronary inter-
vention,arrhythmiaablation,device implantation),has increasedthe
possible risk of “pericardial complications,” with even minor intra-
Box 1. Etiology of Pericarditisa
Infectious Causes
Viral (common): Enteroviruses (especially Coxsackieviruses, echo-
viruses); herpesviruses (especially Epstein-Barr virus, cytomegalo-
virus, human herpesvirus 6); adenoviruses (especially in children);
parvovirus B19
Bacterial:Mycobacterium tuberculosis (common; other rare),
Coxiella burnetii, Borrelia burgdorferi; rarely other microorganisms,
usually as purulent pericarditisb
Fungal (rare):Histoplasma species (more likely in immunocompe-
tent patients); Aspergillus, Blastomyces, and Candida species
(more likely in immunocompromised host)
Parasitic (rare): Echinococcus and Toxoplasma species
Noninfectious Causes
Autoimmune and autoinflammatory (common)
Systemic autoimmune (especially systemic lupus erythematosus,
Sjögren syndrome, rheumatoid arthritis, scleroderma)
Systemic vasculitides (especially eosinophilic granulomatosis
with polyangiitis or allergic granulomatosis, previously named
Churg-Strauss syndrome, Horton disease, Takayasu disease,
Behçet syndrome)
Autoinflammatory diseases (familial Mediterranean fever, tumor
necrosis factor receptor–associated periodic syndrome)
Other (sarcoidosis, inflammatory bowel diseases)
Neoplastic
Primary tumors (rare; pericardial mesothelioma)
Secondary metastatic tumors (common; lung and breast cancer,
lymphoma)
Metabolic (common):Uremia, myxedema, anorexia nervosa,
other rare
Traumatic and iatrogenic (common)
Early onset: Direct injury (penetrating thoracic injury, esophageal
perforation); indirect injury (nonpenetrating thoracic injury,
radiation injury)
Delayed onset: Pericardial injury syndromes (post–myocardial
infarction syndrome, postpericardiotomy syndrome);
posttraumatic, including after iatrogenic trauma (eg, coronary
percutaneous intervention, pacemaker lead insertion, and
radiofrequency ablation)
Drug related (rare)
Lupus-like syndrome (procainamide, hydralazine, methyldopa,
isoniazid, phenytoin)
Hypersensitivity pericarditis with eosinophilia (eg, penicillins)
Pericardial andmyocardial involment (eg, antineoplastic drugs:
doxorubicin, daunorubicin, cytosine arabinoside, fluorouracil,
cyclophosphamide)
a The pericardiummay be affected by all categories of diseases, including
infectious, autoimmune, neoplastic, iatrogenic, traumatic, andmetabolic.
b Pneumococcus,Meningococcus, Gonococcus, Streptococcus,
Staphylococcus,Haemophilus, Chlamydia,Mycoplasma, Legionella,
Leptospira, and Listeria species and Providencia stuartii.
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pericardial bleeding potentially causing pericarditis (pericardial in-
jury syndromes).12,26
Clinical Presentation
The classic and most common presentation of patients with peri-
carditis is chest pain. The chest pain is typically sharp and pleuritic,
improvedbysittingupand leaning forward.Additional signs inacute
pericarditis include(1)pericardial frictionrubs, reported inaboutone-
third of cases with acute pericarditis and due to increased friction
of inflamedpericardial layers; (2) a “typical electrocardiogram”with
widespread ST-segment elevation, reported in nomore than 60%
of cases (Figure 1); and (3) pericardial effusion (usually mild), de-
tected in about 60% of patients (Figure 2).1,2 Specific features at
presentation (temperature>38°C[>100.4°F], subacutecourse, large
effusion or tamponade, and failure of nonsteroidal anti-
inflammatory drug [NSAID] therapy) are useful indicators of a poor
prognosis. Thesecharacteristics also identifypatients requiringhos-
pitaladmission, thusallowingtriageofpatientswithpericarditis, since
the presence of 1 or more of these features indicates the need for
hospitalization (eFigure 2 in the Supplement).19
Assessment and Diagnosis
The only available international guidelines on pericardial diseases
were published in 2004 by the European Society of Cardiology
(ESC)27 for the first time and updated in 2015.28 Although the first
edition did not provide criteria for diagnosing pericarditis, the 2015
ESCupdatedguidelines28acknowledgedandadopteddiagnosticcri-
teria published inmore recent clinical trials2,14 (level of evidenceC).
The diagnosis of acute and recurrent pericarditis is based on spe-
cific clinical criteria (Box 2). Somepatientsmay presentwith recur-
rent chestpainwithoutobjectiveevidenceofdisease.Thisphenom-
enon ismore common among people with chronic pericarditis and
Figure 1. Widespread ST-Segment Elevation and PR-Segment Depression in a 12-Lead Electrocardiogram From a PatientWith Acute Pericarditis
Widespread ST-segment elevation, considered characteristic of pericarditis, can be
found in nomore than60%of patientswith acute pericarditis and ismore
common in youngermale patients, especially in associationwithmyocarditis.3,51
PR depression is especially evident in inferior leads (II, aVF, III) and precordial leads
(V2-V6). Electrocardiogram (ECG) findingsmay be affected by timing in the course
of the disease and by treatment. Early in the disease, ECG changesmay include
ST-segment elevation. Later in the disease and in chronic pericarditis, the ECGmay
be normal or have negative Twaves, reflecting an ECG in evolution. In patients
with a rapid response tomedical therapy and inmild acute pericarditis, the ECG
may be normal. Thus, a normal ECGdoes not exclude pericarditis.
Table 1. Reported Etiology of Pericarditis in Published Series
Etiology
Reported Frequency as Percentage of Reported Cases
of Pericarditis
Idiopathic5,6,9,19,23-26 15% (Africa) to 80%-90% (Europe and United States)
Infectious
Viral (eg, Coxsackievirus, Epstein-Barr virus,
cytomegalovirus, human immunodeficiency virus,
parvovirus B19)5,6,9,19,23-26
Largely unknown (30%-50% in Marburg, Germany experience)
Bacterial9,19,23-26
Tuberculosis 1%-4% (Italy, Spain, France), up to 70% (Africa)
Purulent <1% (Europe) to 2%-3% (mainly Africa); rare (largely unknown)
Other infectious causes9,19,23-26
Noninfectious
Neoplastic etiology9,19,23-27 5%-9% to 35% (in tertiary European referral centers)
Autoimmune9,19,23-25,a 2%-24%
Other Rare (largely unknown)
a Systemic inflammatory disease and
pericardial injury syndromes.
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in patients treated with corticosteroids. However, limited data are
available. In a prospective cohort study of 275 patients with acute
pericarditis, recurrent pain that did not meet objective criteria for
pericarditis recurrence was reported in about 10% of patients. Fe-
male sex (odds ratio [OR], 4.3; 95% CI, 1.8-10.6), previous cortico-
steroiduse (OR,5.2;95%CI,2.2-12.3), andrecurrentpericarditis (OR,
3.7; 95%CI, 1.3-10.2)were associatedwith a higher incidence of re-
current chest painwithout objective evidence of pericarditis.29 Af-
ter amean follow-up of 40months, these patients had a higher re-
currencerate thatmetdiagnosticcriteria (33.3%vs14.1%;P = .02).29
Inpatientswithoutasymptom-freeintervalofat least4to6weeks
(generally thedurationofproposedmedical therapyanddrug taper-
ingforpericarditis), theterm incessantpericarditishasbeenproposed
byexpertsratherthan recurrentpericarditisbecause it ischaracterized
by continuous or intermittent symptomswithout remission.2,28
In addition to thediagnostic criteria specified above, a consen-
sus statement of the American Society of Echocardiography on in-
tegrated cardiovascular imagingof pericardial diseases,20 elevated
or ultrasensitive C-reactive protein, and late gadolinium enhance-
ment of pericardium on cardiac magnetic resonance imaging were
proposed as additional confirmatory criteria of pericarditis (level of
evidence C).
Limiteddataareavailable regarding thediagnosticutilityofperi-
cardial fluid analysis. Pericardiocentesis is usually not indicated in all
patients presenting with acute pericarditis. Specific indications for
pericardiocentesis include cardiac tamponade, large symptomatic
pericardial effusion not responsive to medical therapy, and sus-
pected bacterial or neoplastic etiology. Biochemical and cell-count
composition are generally not helpful for diagnosing most
pericarditis.30 Data on sensitivity and specificity of other pericardial
fluid diagnostic tools are limited to specific laboratory tests for diag-
nosing tuberculous or neoplastic pericarditis (eTable 2 in the
Supplement).31-36Contemporarydiagnosisandmanagementofperi-
carditismaybestbeaccomplishedwithan integrated,multimodalap-
proach. Two recent consensus documents, one from the American
Society of Echocardiography20 andone from theEuropeanAssocia-
tion of Cardiovascular Imaging,21 provide imaging and diagnostic
considerations based on expert opinion (level of evidence C). Multi-
modal imaging, including first-level imaging techniques such as
echocardiography and chest x-ray (Figure 2 and Figure 3) and
second-level imaging techniques such as computed tomography
and cardiacmagnetic resonance, allows detection and confirmation
of pericardial inflammation (Figure 4), evaluation of pericardial
thickness and assessment of the presence of constrictive and/or ef-
fusive-constrictivephysiology, andestablishmentof thediagnosisof
pericarditis indoubtful cases.These techniquesalsoallow identifica-
tion of potentially reversible constriction due to pericardial
inflammation.20-22Additionaldiagnostic testing iswarranteddepend-
ing on specific clinical suspicion (eTable 3 in the Supplement).
Treatment of Idiopathic, Viral,
and Immune-Mediated Pericarditis
Aspirin or NSAIDs
NSAIDs are the mainstay of medical therapy for acute and recur-
rent pericarditis (Table 2) that is idiopathic or viral in etiology (ie, in
the absence of a specific cause that may require targeted therapy
suchastuberculousandotherbacterialetiologiesandneoplasticperi-
cardial disease). Only a single clinical trial evaluated the efficacy of
NSAIDs, and it was conducted in patientswith postpericardiotomy
syndrome, a specific formofpericarditis (level of evidenceB). In this
double-blind RCT of a 10-day course of ibuprofen or indomethacin
vs placebo in 149 patients with postpericardiotomy syndrome af-
ter cardiac surgery,11 drug efficacy was defined as resolution of at
least 2 of the following: fever, chest pain, and friction rub within
Figure 2. Transthoracic 2-Dimensional Echocardiogram Images From 2 PatientsWith Acute Pericarditis
Pericardial effusion
LV
LA
Aortic valve
Mitral valve
A Parasternal long-axis view showing acute pericarditis without pericardial 
effusion
B Parasternal long-axis view showing acute pericarditis with pericardial 
effusion
LV
LA
Aortic valve
Mitral valve
A,Parasternal long axis viewshowing “dry” (withoutpericardial effusion) acute
pericarditis characterizedby increasedbrightness of thepericardial layers,
a nonspecific echocardiographic sign associatedwith fibrinouspericarditis.
B, Parasternal long axis viewshowing amoderate (10-20mmof telediastolic
echo-free space) pericardial effusion. Semiquantitative assessmentof pericardial
effusion is performedmeasuring the largest telediastolic echo-free space in
different echocardiographic views.Amild effusion is definedas <10mm;moderate,
between 10and20mm;and large, >20mm.5,19 A largeeffusion is associatedwith
an increased risk of complications andwith specific etiologies (nonidiopathic
pericarditis; nonviral pericarditis). About60%ofpatientswith acutepericarditis
will have apericardial effusion, generallymild.5,19 Theabsenceof apericardial
effusiondoesnot excludepericarditis. LA indicates left atrium; LV, left ventricle.
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48 hours. Ibuprofen and indomethacinwere 90.2%and88.7%ef-
fective, respectively.Bothweresignificantlymoreeffective thanpla-
cebo (62.5%; P = .003).
Corticosteroids
Corticosteroid therapywas previously the initial choice for treating
pericarditis with pericardial effusions or recurrences not respond-
ing to aspirin or NSAIDs. However, more recently, this therapy has
been shown to be associatedwithmore adverse effects, possibly a
moreprolongeddisease course, andahigher recurrence risk innon-
randomizedstudies (levelofevidenceB). In the largest suchstudy,22
100 consecutive patients with recurrent pericarditis (either idio-
pathic or associatedwith a systemic inflammatory disease or post-
cardiac injury syndrome) were evaluated according to a protocol
comparing high-dosage prednisone (1.0 mg/kg per day) vs low- to
moderate-dosage prednisone (0.2-0.5mg/kg per day). Each initial
dosewasmaintained for4weeksand thenslowly tapered.After ad-
justing for confounders (age, female sex, nonidiopathicorigin), only
highdosagesofprednisonewereassociatedwith severeadverseef-
fects, recurrences, andhospitalizations (hazard ratio [HR],3.61;95%
CI, 1.96-6.63). Hospitalizationswere lower in patients treatedwith
low- vs high-dosage prednisone (8.2% vs 31.4%, respectively;
P = .005). Use of low to moderate dosages of corticosteroids was
associated with a lower recurrence rate during follow-up com-
pared with high dosages (eg, prednisone, 1.0 mg/kg/d) (32.6% vs
64.7%; P = .002).
Colchicine
Considerable evidence supports using colchicine as an adjunct to
NSAIDs to improve remission rates at 1 week and reduce recur-
rence rates in both acute1,2 and recurrent pericarditis14,16,18 com-
pared with NSAIDs alone (level of evidence A).
Themain knownanti-inflammatory effect of colchicine is block-
ade of tubulin polymerization with impaired microtubule assembly,
thus inhibiting the pro-inflammatory functions of white blood cells,
especially granulocytes, where colchicine concentrates. In a
meta-analysis37 including 7 studies ofmedical therapy for pericardi-
tis (idiopathic, viral, ordueto inflammatorysystemicdiseaseorpost–
cardiac injury syndrome) that included451patients, treatment com-
parisons were colchicine plus NSAIDs vs NSAIDs only (3 RCTs; 265
patients), corticosteroids vs NSAIDs (2 observational studies; 31 pa-
tients), low-dosage vs high-dosage corticosteroids (1 observational
study; 100 patients), and statins vs standard therapy (1 RCT; 55 pa-
tients).Colchicinewasassociatedwithareducedriskoftreatmentfail-
ure(OR,0.23;95%CI,0.11-0.49)andrecurrentpericarditis (OR,0.39;
95%CI,0.20-0.77).Themostcommonadverseeventassociatedwith
colchicine is gastrointestinal intolerance, especially diarrhea, re-
ported in 7% to 10% of patients receiving colchicine therapy. Low-
dosagecorticosteroids (eg,prednisone,0.2-0.5mg/kgperday)were
associated with lower rates of recurrence or treatment failure (OR,
0.29; 95% CI, 0.13-0.66), hospitalizations (OR, 0.19; 95% CI, 0.06-
0.63), and adverse effects (OR, 0.07; 95%CI, 0.01-0.54) compared
withhigh-dosagecorticosteroids (eg,prednisone1.0mg/kgperday).
Data on statins were inconclusive and derived from a single-center
studywithout additional supporting evidence.
Additionalmeta-analyses38-40 including the lastRCT13 reported
thatcolchicineusewasassociatedwitha reducedriskofpostpericar-
diotomysyndrome(OR,0.48;95%CI,0.33-0.68)andrecurrentperi-
carditis in patients with acute pericarditis (OR, 0.31; 95% CI, 0.19-
0.52)or recurrentpericarditis (OR,0.31;95%CI,0.20-0.46) (levelof
evidence A). The use of colchicinewas associatedwith an increased
Box 2. Diagnostic Criteria
Diagnostic Criteria for Acute Pericarditis
At least 2 of the following clinical criteria are required:
Chest pain (typically sharp and pleuritic, improved by sitting up
and leaning forward)
Pericardial friction rub
Suggestive changes on electrocardiography (widespread
ST-segment elevation or PR depression) (Figure 1)
New or worsening pericardial effusion (Figure 2).
Diagnostic Criteria for Recurrent Pericarditis
The following 3 criteria are all present:
Documented first attack of acute pericarditis according to
diagnostic criteria
Symptom-free interval of 4 to 6 weeks or longer
Evidence of subsequent recurrence of pericarditis by recurrent
pain combinedwith 1 ormore of the following signs: pericardial
friction rub, changes on electrocardiography, echocardiographic
evidence of new orworsening pericardial effusion, and elevation
inwhite blood cell count, erythrocyte sedimentation rate,
or C-reactive protein level (any value above the upper limit of
normal for the laboratory)
Additional Supportive Criteria for Pericarditis
(Either Acute or Recurrent)
Elevation of markers of inflammation (eg, C-reactive protein)
Evidence of pericardial inflammation by an imaging technique
(eg, contrast-enhanced pericardium on computed tomography or
pericardial edema and pericardial late gadolinium enhancement on
cardiac magnetic resonance imaging)20,28
Figure 3. Posterior-Anterior Chest Radiograph of a PatientWith
Acute Pericarditis
Water bottle–shaped cardiac silhouette characteristic of a large pericardial
effusion in a patient with acute pericarditis. Chest radiograph findings in
patients with acute pericarditis are typically normal unless there is concomitant
pleuropulmonary disease or a very large pericardial effusion (>300mL).
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risk of adverse events (mainly diarrhea; OR, 1.45; 95%CI, 1.04.2-03)
and drug discontinuation (OR, 1.40; 95%CI, 1.00-1.94).
Inmorerecenttrials,efficacywasachievedwithoutan initial load-
ingdoseandbyprescribingweight-adjusteddosages(eg,0.5mgtwice
daily inpatients>70kgand0.5mgoncedaily inpatients70kg).2,14
On thisbasis,weight-adjusteddosingof colchicinewithout a loading
dose is recommended in patients with acute and recurrent pericar-
ditis in addition to aspirin or anNSAID (level of evidence A).
New Therapeutic Options for Recurrent Pericarditis After Failure
of Colchicine Treatment
Optimalmanagementofpatientswithmultiple recurrencesandpa-
tients either who do not tolerate colchicine or in whom colchicine
therapyhas failed is unclear. There is limitedevidence to support al-
ternative therapies including oral azathioprine,41 intravenous hu-
man immunoglobulins,42,43 and anakinra (an interleukin-1 receptor
antagonist).44,45 In themanagement of recurrent pericarditis, aza-
Figure 4. CardiacMagnetic Resonance Images From a PatientWith Acute Pericarditis
Late gadolinium enhancement CMRC
D Real-time CMR cine images
Expiration
LVLV
T1-weighted CMRA
LV
RV
B STIR T2-weighted CMR 
Inspiration
Findings characteristic of acute
pericarditis that may be observed
with cardiac magnetic resonance
(CMR) imaging include pericardial
thickening and evidence of
pericardial edema. A, T1-weighted
4-chamber view showing thickened
pericardium (yellow arrowhead).
B, STIR T2-weighted
4-chamber view showing a
pericardial hyperintense signal
(yellow arrowhead) that indicates
increased pericardial edema and left
pleural effusion (black arrowhead).
C, Late gadolinium enhancement
4-chamber view showing late
enhancement of the pericardium
(yellow arrowhead). Late gadolinium
enhancement may persist beyond
the acute phase of pericarditis
indicating organizing pericarditis
(chronic inflammatory pericarditis
and fibrosis). D, Real-time
free-breathing cine images,
midventricular short-axis views,
in expiration (left) and inspiration
(right) showing septal flattening
during inspiration (blue arrowhead),
indicating accentuated
interventricular independence.
Images courtesy of Patrizia Pedrotti,
MD, Giuseppina Quattrocchi, MD,
and Alberto Roghi, MD, Ospedale
Niguarda, Milan, Italy.
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thioprineacts as immunosuppressive therapywhile intravenous im-
munoglobulins and anakinra act as immunomodulatory agents.
Forpatientswith refractory recurrentpericarditis that is not re-
sponsive to anymedical therapy, the last therapeutic option is peri-
cardiectomy. However, this therapy is only supported by a retro-
spective series from the Mayo Clinic, which demonstrated that
patients with recurrent pericarditis who received surgery experi-
enced fewer relapses than patientswith recurrent pericarditiswho
receivedmedical therapy (level of evidenceC).46 In contrast, a small
retrospective study found that few patients (2 of 9 patients) re-
sponded to pericardiectomy.47 Both of these studies are limited by
their retrospective design.
Prognosis
An Italian prospective cohort study evaluated the risk of complica-
tions during follow-up of 453 patients aged 17 to 90 years.19 A spe-
cific cause of pericarditis was found in 76 patients (16.8%). The eti-
ologyofpericarditiswasautoimmunein33patients(7.3%),neoplastic
in23(5.1%), tuberculous in17(3.8%),andpurulent in3(0.7%). Inmul-
tivariable analysis, female sex (HR, 1.67; 95% CI, 1.03-2.70; P = .04)
and patients with fever higher than 38°C or 100.4°F (HR, 3.56; 95%
CI, 1.82-6.95; P < .001), subacute course (HR, 3.97; 95% CI, 1.66-
9.50;P = .002), largeeffusionor tamponade(HR,2.15;95%CI, 1.09-
4.23; P = .03), and failure of NSAID therapy (including aspirin) (HR,
2.50, 95% CI, 1.28 to 4.91; P = .008) were associated with an in-
creased incidence of an identifiable cause of the pericarditis. After a
mean follow-up of 31 months, the following complications were de-
tected in 95 patients (21.0%): recurrences in 83 (18.3%), tampon-
ade in 14 (3.1%), and constriction in 7 (1.5%). Inmultivariate analysis,
femalesex(HR,1.65;95%CI, 1.08-2.52;P = .02), largeeffusionortam-
ponade (HR, 2.51; 95% CI, 1.37-4.61; P = .003), and failure of NSAID
therapy (HR,5.50;95%CI,3.56-8.51;P < .001)wereassociatedwith
an increased risk of complications, which were reportedmore com-
monly inpatientswithanonidiopathicetiologyofpericarditis.Onthis
basis, specific clinical features (fever >38°C or >100.4°F, subacute
course, large effusionor tamponade, andNSAID/aspirin therapy fail-
ure) were proposed as indicators of an identifiable cause of pericar-
ditis and poor prognosis and, in addition, a rationale for hospital ad-
mission (level of evidence B) (eFigure 2 in the Supplement).
A single prospective cohort study evaluated complication rates
inpatientswithpericarditis of varyingetiologieswith a special focus
ontheriskofdevelopingconstrictivepericarditis.7Fivehundredcon-
secutive cases with a first episode of acute pericarditis (age 51 ± 16
years; 270 men) were prospectively studied. Etiologies were viral/
idiopathic in 416 cases (83.2%), connective tissue disease/
pericardial injury syndromes in 36 (7.2%), neoplastic pericarditis in
25 (5.0%), tuberculosis in20 (4.0%), andpurulent in3 (0.6%).Dur-
ing a median follow-up of 72 months (range, 24-120months), con-
strictive pericarditis developed in 9 of 500patients (1.8%): 2 of 416
patients with idiopathic/viral pericarditis (0.48%) vs 7 of 84 pa-
tientswithotheretiologies (8.3%).The incidenceofconstrictiveperi-
carditiswas0.76casesper1000person-yearsfor idiopathic/viralperi-
carditis, 4.40 cases per 1000 person-years for connective tissue
disease/pericardial injury syndrome, 6.33 cases per 1000 person-
years for neoplastic pericarditis, 31.65 cases for 1000 person-years
for tuberculouspericarditis, and52.74casesper 1000person-years
for purulent pericarditis. This study indicates that development of
constrictive pericarditis is related to etiology (level of evidence B).
Pericarditis andmyocarditismay coexist in 20% to 30%of pa-
tientspresentingwitha clinical suspicionofpericarditis due toover-
lappingetiologies (all causesofpericarditis are alsopotential causes
ofmyocarditis).48-51 Thepresenceof concomitantmyocarditis is of-
ten indicated by elevation of serum troponins. Patients with peri-
carditis concomitantwithmyocarditis (usually referredasmyoperi-
carditis) have potential for a higher rate of complications including
left ventricular dysfunction and heart failure. In a recently pub-
lished systematic review of myopericarditis,49 8 major clinical se-
rieswere includedwitha total of 389patients (meanage, 31.7 years;
male-female ratio, 4.0). After a mean follow-up of 31 months, re-
sidual leftventriculardysfunctionwasreported in3.5%withnocases
of heart failure. Recurrences occurred in 13.0% of cases, mainly as
recurrent pericarditis (>90%), with cardiac tamponade and con-
strictive pericarditis in less than 1% of cases.
In the largest study,23 no deaths were recorded, there was no
progression to heart failure, and troponin elevation was not asso-
ciatedwithan increase in complications (level of evidenceB). In this
study, a clinical diagnosis of myopericarditis was made in patients
with a definite diagnosis of acute pericarditis and elevation of car-
diacmarkers of injury (troponin I or T, creatine kinase–MB fraction)
Table 2. Therapies for Acute and Recurrent Pericarditis by Indication
and Rating Based onQuality of Available Evidencea
Therapy
Level of
Evidenceb Mechanism of Action
Aspirin/nonsteroidal
anti-inflammatory drugs
Aspirin, 750-1000mg 3 times
daily; ibuprofen, 600mg 3 times
daily; indomethacin, 25-50mg 3
times daily; all usually for 1-2 wk
in acute pericarditis and 2-4 in
recurrent pericarditis, then
tapered11,30,bc
B Inhibition of the activity
of both cyclooxygenase-1
and cyclooxygenase-2
and thereby the synthesis
of prostaglandins
Colchicine, 0.5 mg twice daily or
once daily for 3 mo (acute) or 6 mo
(recurrent); once daily if weight
≤70 kg1,2,14,16,18,30-33
A Blocking of tubulin
polymerization, reduction
of microtubule and
granulocyte function
Corticosteroids, 0.2-0.5 mg of
prednisone or equivalent, usually for
2-4 wk, then tapered1,18,19,30,c
B Suppression of most
components of the
inflammatory process
Azathioprine, 1.5-2.5 mg/kg per d
for several mo34
C Blocking of purine and DNA
synthesis and inhibition
of lymphocyte proliferation
Intravenous immunoglobulins
(400-500mg/kg per d for 5 d)35
C Modulation of adaptive
and innate immunity
and increased clearance
of infectious agents
Subcutaneous anakinra (1-2 mg/kg
per d up to 100mg for several mo)37
C Competition with
interleukin 1 and reduction
of interleukin-1 activity
a Including largest studies on adult populations. These therapies are indicated
for idiopathic and nonbacterial etiologies.
bAvailable levels of evidence for each diagnostic intervention were reviewed
and classified according to American Heart Association/American College of
Cardiology guidelines as follows: level A if data are available frommultiple
populations based on clinical trials or registries delineating usefulness/efficacy
in various subpopulations; level B if limited populations have been evaluated
and/or data are derived from a single randomized clinical trial or
nonrandomized studies; and level C if very limited populations have been
evaluated or only consensus opinion of experts, case studies, and unverified
standards of care are available.
c Until symptom resolution and normalization of markers of inflammation
(eg, C-reactive protein).
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withoutnewonsetof focalordiffusedepressed leftventricular func-
tion by echocardiography or cardiac magnetic resonance imaging.
A systematic review of all published cases of idiopathic recur-
rent pericarditiswithoutmyocarditis52 included8major clinical se-
ries with a total of 230 patients (mean age, 46 years; male-female
ratio, 0.9). After a mean follow-up of 61 months, cardiac tampon-
ade occurred in 3.5%of cases, and no cases of constrictive pericar-
ditis or left ventricular dysfunction occurred. The overall prognosis
was excellent in idiopathic recurrent pericarditis with lowmorbid-
ity rates, leading to the conclusion that constrictive pericarditis vir-
tually never occurs after idiopathic pericarditis, even though idio-
pathic pericarditis can recur (level of evidence C), and the risk is
actually lower than in idiopathic acute pericarditis without recur-
rence, in which the reported risk is approximately 1%.
Clinical Practice Guidelines
International practice guidelines for pericarditis were recently up-
dated by the ESC.28 The guidelines incorporate diagnostic criteria
and a new set of recommendations that are mainly based on ex-
pert opinion. Similarly, recent consensus updates focus on multi-
modal imaging of pericardial disease and are mainly based on ex-
pert opinion (eTable 4 in the Supplement).20,21
The findings of the review are consistent with current clinical
practiceguidelines, that,however,provideespeciallyaEuropeanper-
spective.On this basis, there is a need for additional research to ad-
dress potential issues related to different ethnicities and develop-
ing countries.
Discussion
Thediagnosisofpericarditis shouldbebasedonclinical criteria (Box
2). Basic diagnostic assessment (clinical evaluation, electrocardio-
gram, routine blood chemistry, markers of inflammation andmyo-
cardial lesion (eg, troponins), chest x-ray, andechocardiogram)may
allow the clinician to select patients at high risk of nonidiopathic/
nonviral etiologies and complications warranting hospital admis-
sion, as well as appropriate diagnostic evaluation.
Based mainly on expert consensus, a single RCT in the setting
of thepostpericardiotomysyndrome,11 andameta-analysis (level of
evidence B),37 the mainstay of anti-inflammatory therapy for non-
bacterial causesofpericarditis is anNSAID,most commonly ibupro-
fenor aspirin.28Colchicine shouldbe combinedwith standard anti-
inflammatory therapytohastentheresponsetomedical therapyand
prevent recurrences inpatientswithnonbacterial causes.This state-
ment is supportedbyseveralRCTs,1,2,14,16,18meta-analyses,37-40and
the 2015 ESC guidelines28 (level of evidence A). In the absence of a
specific indication(eg, systemic inflammatorydiseases requiringcor-
ticosteroids, pregnancy), corticosteroids are associatedwith an in-
creased risk of recurrences,23,37 especiallywhen prescribed in high
dosages (eg, prednisone, 1 mg/kg per day)23 (level of evidence A).
Thus, corticosteroid therapy should be restricted to patients who
do not tolerate NSAIDs or who have contraindications to their use,
and only after failure of first-line therapy combined with colchi-
cine. Newer therapies (eg, intravenous immunoglobulins and
anakinra)maybeconsidered forpatientswhodonot respondtocol-
chicine, but additional evidence is needed to confirm their efficacy.
Pericardiectomy is a final option in experienced surgical centers af-
ter failure of medical therapies.
The optimal duration of anti-inflammatory therapy is unclear.
An individualized approach is advisable. Clinicians should consider
both symptom resolution and normalization of inflammatory bio-
markers (eg, C-reactive protein) to guide the duration of anti-
inflammatory therapy (usually 1-2 weeks).53 Tapering (usually with
anoverall 4- to6-week courseof therapy)maybe considered to re-
duce the riskof recurrences (level of evidenceB). This approachhas
been recently endorsed by the 2015 ESC guidelines.28
The role of nonpharmacological measures is not well estab-
lished, but they are part of the recommended therapy. Although
exercise restriction in the setting of pericarditis has been
recommended,5,6 this recommendation isbasedonlyonexpertopin-
ion, and there are no observational studies or clinical trials for or
against this recommendation (level of evidence C). Currently, exer-
cise restriction is recommendeduntil remission fornonathletes and
until remission but with a minimal arbitrary period of 3 months for
athletes, according to expert consensus.28
There is no clinical trial evidence to guidemanagement ofmyo-
pericarditis. Myopericarditis is associated with low rates of morbid-
ity, mortality, evolution to heart failure, and worsening ventricular
function.49
Futureresearchshouldfocusonspecificsubpopulations:children,
women,elderlypeople,andindividualsofvaryingethnicities.54-56Cur-
rently,mostdataarefromwhitepatients,withonly limiteddata inspe-
cific populations, mainly among those with tuberculous pericarditis
fromsub-SaharanAfrica.8Moreover, furtherprospective studies are
needed to elucidate the etiology and epidemiology of pericarditis as
well as optimal therapies, especially for patientswith recurrent peri-
carditis and those not responsive toNSAIDs and colchicine.
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